Background A considerable proportion of patients with asthma remain uncontrolled or symptomatic despite treatment with a high dose of inhaled glucocorticosteroids (ICSs) and long-acting b 2 -agonists (LABAs). Tiotropium Respimat Ò added to usual care improves lung function, asthma control, and the frequency of non-severe and severe exacerbations, in a population of adult asthma patients who are uncontrolled despite treatment with ICS/LABA. Objective This study estimated the cost effectiveness of tiotropium therapy as add-on to usual care in asthma patients that are uncontrolled despite treatment with ICS/ LABA combination from the perspective of the UK National Health Service (NHS). Methods A Markov model was developed which considers levels of asthma control and exacerbations. The model analysed cost and quality-adjusted life-years (QALYs); sensitivity and scenario analyses were also conducted to test the robustness of the base case outcomes. All costs are given at 2012 prices. Results The model found that in this category of asthma with unmet need, add-on tiotropium therapy generated an incremental 0.24 QALYs and £5,238 costs over a lifetime horizon, resulting in an incremental cost-effectiveness ratio of £21,906 per QALY gained. Sensitivity analysis suggested that findings were most dependent on the costs of managing uncontrolled asthma and the cost of treatment with tiotropium. Conclusion In this modelled analysis of two clinical trials, tiotropium was found to be cost effective when added to usual care in patients who remain uncontrolled despite treatment with high-dose ICS/LABA. Further research should investigate the long-term treatment effectiveness of tiotropium.
Introduction
Asthma is a chronic inflammatory disorder of the airways which is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning [1] . The primary goals of treatment of asthma are the control of symptoms, normalisation of pulmonary respiratory function and the prevention of acute exacerbations [1] .
Approximately 300 million people worldwide have asthma [1] . The Global Initiative for Asthma (GINA) recommends a stepwise escalation of treatment in order to achieve and maintain asthma control [1] . Asthma is defined as 'difficult to treat' if acceptable control is not achieved with the use of two or more controllers. This treatment corresponds with step 4 of the GINA and British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/ SIGN) asthma guidelines and typically comprises a combination of medium-to high-dose inhaled glucocorticosteroids (ICSs) with long-acting b 2 -agonists (LABAs), or alternative controllers [1] [2] [3] .
Patients treated at this level (GINA step 4 [3] ) generate an economic burden associated with direct medical costs that has been estimated to be twice as large as for patients at GINA step 3 [4, 5] . Additionally, the costs of medical resource use for patients with persistent asthma who continue to experience frequent symptoms and exacerbations despite treatment can be around three times larger than for patients whose symptoms remain well-controlled [6] . Once GINA step 4 medications have been exhausted, GINA step 5 options are limited and some (oral glucocorticosteroids) are associated with severe side effects or are only indicated in subgroups of patients [e.g. anti-immunoglobulin E (anti-IgE) treatment]. Others, such as bronchial thermoplasty, are not widely accessible and indications for their use uncertain [1] .
A new option being evaluated for patients on step 4 is the addition of a long-acting anticholinergic bronchodilator. Recently, the efficacy and safety of adding tiotropium administered via the Respimat Ò device as an add-on maintenance controller has been studied. The PrimoTinAasthma Ò trials assessed the change from baseline in peak and trough forced expiratory volume in 1 s (FEV 1 ) and the time to first severe exacerbation as co-primary endpoints. In both trials, the addition of tiotropium resulted in significantly greater changes from baseline in peak and trough FEV 1 . The addition of tiotropium increased time to the first severe exacerbation (282 days as compared with 226 days) and significantly reduced the risk of a severe exacerbation (hazard ratio 0.79, P = 0.03) [7] . Full details of the trial design and results have been published elsewhere [7] .
The objective of this economic evaluation was to estimate, using the PrimoTinA-asthma Ò trials database, the long-term health and cost implications of adding tiotropium to usual care compared with usual care alone in adult patients with asthma that is poorly controlled despite treatment with a combination of high-dose ICS/LABA, from the perspective of the UK National Health Service (NHS).
Methods
The analysis employed a state transition Markov cohort model to investigate the incremental costs and benefits of using tiotropium as add-on therapy to usual care (high-dose ICS/LABA) over a lifetime horizon.
Model Population and Treatments Assessed
The PrimoTinA-asthma Ò clinical trials recruited asthma patients who were poorly controlled, confirmed by an Asthma Control Questionnaire 7 (ACQ-7) score of 1.5 or greater despite usual care comprising at least a high-dose ICS/LABA. In a double-blind parallel-group design with a treatment period of 48 weeks, the intervention was tiotropium 5 lg daily or placebo, both delivered by the Respimat Ò Soft Mist Inhaler device and given in addition to the pre-trial usual care treatment of high-dose ICS/LABA and other controller drugs.
In this analysis, patients were also assumed to receive high-dose ICS/LABA as controller therapy, herein referred to as 'usual care'. For costing purposes (calculations presented in Table 3 ), it was assumed that this corresponded to budesonide 800 lg/formoterol fumarate 24 lg or fluticasone propionate 500 lg/salmeterol 100 lg, representing the lower bounds for ICS/LABA combinations available in the UK that would be considered 'high dose' by current GINA and BTS/SIGN guidelines [1, 2] . In the PrimoTinAasthma Ò clinical trials, further background medication (additional to the high-dose ICS/LABA maintenance treatment) was allowed in both arms if maintained at a stable dose throughout the trial. In the cost-effectiveness model, the use of co-medication was taken into account as resource use that had been informed via a physician survey in order to give a more accurate reflection of clinical practice (Sect. 2.4.3).
Model Structure
Asthma is a chronic disease with fluctuations in day-to-day symptoms and frequent and recurring exacerbations [1] . A Markov modelling framework was developed to reflect differences in day-to-day symptom control and the onset of acute symptomatic episodes, allowing patients to remain in a health state for the duration of a model cycle and at the end of each cycle either remain in the same health state or move to another health state. The cycle length of the costeffectiveness model was set as 1 week, which allows the necessary level detail for representation of the clinical events of interest; in particular, exacerbation events. The time horizon was the remainder of the patient's life; as in the PrimoTinA-asthma Ò clinical trials, the average age of the patient cohort was 53 years at baseline [7] and no patients were assumed to live longer than 100 years.
The model included seven mutually exclusive health states which patients can transition between and reflect the disease pathway: three asthma control health states (controlled asthma, partly controlled asthma, uncontrolled asthma), three exacerbation health states (non-severe exacerbation, severe exacerbation without hospitalisation, severe exacerbation with hospitalisation) and death ( Fig. 1) . The asthma control health states reflect levels of symptom control experienced by patients that are within their typical day-to-day variability; on the other hand, exacerbations reflect a sudden, persistent worsening of asthma outside the usual range of symptoms.
The ACQ score, used to define the asthma control health states, is a composite score that includes measures of daytime asthma symptoms, night-time asthma symptoms, rescue medication use and spirometry. Since spirometry is not carried out routinely in clinical practice, the ACQ-6 score (excluding the spirometry item) was used to categorise patients into the asthma control health states on a weekly basis. Patients with an ACQ-6 score less than 1 were defined as being controlled, those with an ACQ-6 score of at least 1 but less than 1.5 were defined as being partly controlled, and those with an ACQ-6 score greater or equal to 1.5 were defined as having uncontrolled asthma.
The definition of an asthma exacerbation in this analysis was identical to that used in the PrimoTinA-asthma Ò clinical trials; an acute episode of progressive worsening of at least one asthma symptom, which was clinically identified as being outside the patient's usual range of day-today asthma variation lasting for at least 2 days. A severe asthma exacerbation additionally required initiation of treatment with systemic (including oral) glucocorticosteroids for at least 3 days or, in the case of ongoing systemic glucocorticosteroid therapy, requiring at least doubling of previous daily doses for at least 3 days.
Model Transition Probabilities
A sample of 793 patients with complete sets of ACQ data was used to construct model transition probabilities representing 87 % of the 912 patients enrolled in the PrimoTinA-asthma Ò trials. The baseline distribution of patients across the model health states is shown in Table 1 , the asthma control states are defined according to the ACQ-6, and it was assumed that at baseline no patients were experiencing an exacerbation.
In the PrimoTinA-asthma Ò clinical trials the ACQ score was measured at the eight study visits; the first two visits after baseline took place at 4-week intervals and the remaining five visits took place at 8-week intervals. Therefore, imputation was used to categorise patients into one of the six model health states at each week throughout the 48-week trial duration; a patient's previous ACQ-6 score was applied for each week until the next study visit, unless an exacerbation occurred. In that case, the ACQ-6 score from the next study visit was applied once the exacerbation ended. Based on the outcomes of the clinical trials, a non-severe exacerbation was assumed to last for 1 week (average duration reported in PrimoTinA-asthma Ò 7.5 days) and a severe exacerbation for 2 weeks (average duration reported in PrimoTinA-asthma Ò 15.1 days). The time dependence of effectiveness was taken into account by use of a two-phase transition matrix structure. Both treatment arms included an 'early response phase' transition matrix reflecting weekly transition probabilities across the first 8 weeks of the trial duration and was applied for the first eight cycles of the cost-effectiveness model. A 'late response phase' transition matrix reflecting weekly transition probabilities across the remaining 40 weeks of the clinical trial duration was also included in the cost-effectiveness model for both treatment arms. The 'late response phase' transition matrix was applied from the ninth cycle of the cost-effectiveness model and was used to extrapolate effectiveness over the remainder of the time horizon. A Bayesian method, which is based on the observed number of weekly patient transitions from the clinical trials, was used to construct the model transition probabilities [8] . Further details on this method and the resulting transition probability matrices can be found in the Technical Appendix provided as Electronic Supplementary Material to this article.
Transitions into death are possible from any model health state. However, since no deaths had been observed in the entire tiotropium in asthma clinical trial programme, and asthma deaths are rare, the model did not assume elevated asthma related mortality in the base case and mortality was derived from standard life tables [9].
Model Inputs

Health State-Specific Utilities
The EuroQol EQ-5D scores were collected at each of the study visits and the mean scores estimated for each of the asthma control health states were converted into utility values using the UK-based EuroQol tariff [10] . No significant difference in average utility scores for each asthma control category was observed between treatment arms. The average utility scores collected at study endpoint were used as model inputs for these health states.
Since exacerbations only rarely coincided with study visits, utilities associated with severe asthma exacerbations had to be derived from published sources [11] . The severe exacerbation utility estimates used in the model have been derived from a study that collected EQ-5D scores from a sample of 112 asthma patients in the UK [11] . Utility estimates for outpatient-managed exacerbations have been reported in literature [12] [13] [14] ; however, no literature was found to provide a value for the utility of the non-severe exacerbation model health state as defined in this analysis. Therefore, an assumption was made that this value was the average between the values for uncontrolled asthma and for a severe exacerbation without hospitalisation. This estimated utility value of a non-severe exacerbation (0.649) was very similar to those reported in the literature for outpatient-managed exacerbations (0.65-0.67) [12] . A summary of the utilities used in the model is presented in Table 2 . Utilities were discounted at a rate of 3.5 % per annum.
Study Medication Costs
Cost for usual care was derived by an equal weighting of the costs of the two relevant high-dose ICS/LABA combination products available on the UK market ( Table 3) . The lower dose limit of the GINA-recommended high-dose range was conservatively used to cost usual care [1] . The cost of usual care medication was £8.52 per 7-day cycle and the cost of tiotropium was £8.28 per 7-day cycle (Table 3 ). All costs included in the cost-effectiveness model were obtained at 2012 prices discounted at a rate of 3.5 % per annum.
Health State Costs
Non-medication costs were assigned to each model health state and applied for each model cycle that a patient spent in a health state. These health state-specific costs consider inpatient resource use, outpatient visits, home visits, tests and procedures, and co-medication use. This information was collected throughout the PrimoTinA-asthma Ò clinical trials; however, given that the patients in the trial had frequently scheduled outpatient study visits (eight in 48 weeks), the analysis of asthma-related additional (unscheduled) visits resulted in numbers that were judged to be unrealistically low.
Therefore, a survey (presented in the technical appendix) was conducted which asked 15 UK healthcare providers (five general practitioners experienced with treating asthma patients, five asthma specialists and five respiratory nurses) to make health state-specific estimates of the use of outpatient visits, home visits, diagnostic tests and treatment procedures, and co-medications by asthma patients being treated at GINA step 4. The resources utilised were per quarter of a year, or per exacerbation event. The mean Ò clinical trials when they occurred and were therefore removed from the trial schedule. Hence, the records of such hospitalisations within the clinical trial were regarded as reliable and could be used for the model inputs. Further information on rescue medication usage (salbutamol) was taken from the clinical trials.
The estimates of resource use are shown in Table 4 . The weekly health state costs (Table 5) were calculated by multiplying each of these elements of resource use by its unit cost. The unit costs (obtained at 2012 prices) used to value outpatient visits were obtained from the Unit Costs of Health and Social Care 2012 [15] , unit costs for inpatient resource use and test and procedure use were obtained from the National Schedule of Reference Costs 2011/2012 [16] , and unit costs for study medication, co-medications and rescue medication were obtained from the British National Formulary (BNF) No. 65 (February 2013) [17] .
Rescue medication usage was derived from PrimoTinAasthma Ò data and differed by model health state and by treatment arm. Table 6 shows the weekly cost of rescue medication use.
Analyses Conducted
The base-case analysis compared the incremental costs and incremental quality-adjusted life-years (QALYs) generated by tiotropium in add-on to usual care to a strategy of usual care alone over a lifetime horizon for a cohort of adult asthma patients uncontrolled on ICS/LABA combination therapy.
To test the impact of changing health state costs, utility inputs and rescue medication costs, a one-way sensitivity analysis (OWSA) was conducted. The upper and lower bounds of the 95 % confidence intervals around each element of resource use included in the health state costs were used to calculate an upper and lower bound of each health state-specific cost. Similarly, confidence limits around the rescue medication use estimates were used to derive upper and lower bounds of the health state-specific rescue medication costs. 95 % confidence intervals were used to assess the impact of uncertainty in the utility values obtained from a Assumed to be equal to the average standard error across the three asthma control health states The impact of model uncertainty was assessed in a probabilistic sensitivity analysis (PSA). Log-normal distributions were fitted around the resource use and rescue medication use input values and beta distributions were fitted around the utility input values. These distributions are shown in the Technical Appendix. The stability of the model transition probabilities is a key component of model uncertainty; therefore, in the PSA all transition probabilities were simultaneously varied. Due to the inter-dependence between model transition probabilities, the impact of uncertainty around the transition probabilities was assessed in the PSA by use of an approximation to the Dirichlet distribution [8] . In the PSA, values were randomly sampled for these inputs. All distributions were stochastically sampled for 10,000 iterations and outputs for incremental costs and QALYs were recorded.
Although the base-case assumed no asthma-specific mortality, a scenario analysis was conducted that examined the impact of a mortality rate associated with severe hospitalised exacerbations. This scenario analysis was based on the results of a literature review conducted for a recent National Institute for Health and Clinical Excellence (NICE) submission on asthma [18] identifying a publication on the mortality risk from asthma admissions in the UK [19] . In this publication, Watson et al. [19] reported that a non-intensive care unit admission for severe acute asthma was associated with a mortality rate of 0.383 % for ages 17-44 years, and 2.478 % for ages 45 years and over, when patients who died on the day of admission are not considered. In the scenario analysis, these values were used to estimate the mortality rate following a severe exacerbation with hospitalisation. Scenario analyses that examine the impact of assuming shorter time horizons of analysis (48 weeks, 3 years and 5 years) were also conducted.
Results
Base-Case Results
In the base case, tiotropium added to usual care was found to increase lifetime discounted costs by £5,238 for an additional 0.24 QALYs gained compared with usual care alone. This resulted in an incremental cost-effectiveness ratio (ICER) of £21,906 per QALY gained.
The cost breakdown by health state is presented in Fig. 2 and the proportion of the cohort in each health state over the time horizon is shown in Figs. 3 and 4 for the tiotropium and usual care arms, respectively. The largest part of the costs accrued due to healthcare costs of the state 'uncontrolled asthma' as patients spent most of their time in this state. The total costs of the three exacerbation states were lower for tiotropium added to usual care than for usual care alone, as fewer patients suffered from exacerbations when receiving add-on tiotropium.
The QALY breakdown by health state found that treatment with tiotropium generated a QALY gain driven by (Table 7 ; Fig. 3 ).
Sensitivity Analyses
The results of OWSA for tiotropium added to usual care versus usual care alone are summarised in a tornado diagram in Fig. 5 . The chart labels on Fig. 5 indicate the names of the variables that generated a spread of the ICER, which was at least 5 % of the base-case value of the ICER (£21,906). All variables included in the OWSA and not included on the tornado diagram had a smaller impact on the spread of the ICER. The figures in brackets after each variable name show the lower bound of the variable used in the OWSA, the base-case value of the variable and the upper bound of the variable used in the OWSA. The highest impact on the ICER value was seen for variation in the cost of the 'uncontrolled asthma' health state. When considering variations in the key model inputs, the ICER remained below £30,000 per QALY gained. The results of the PSA are shown on a cost-effectiveness plane plotting incremental costs against incremental QALYs (Fig. 6) . Approximately 98 % of iterations appear in the north-east quadrant of the costeffectiveness plane, suggesting that tiotropium add-on therapy to usual care is more costly and more effective than usual care alone and needs evaluation against a willingness to pay per QALY threshold. The dotted diagonal line indicates a willingness to pay of £30,000 per QALY gained and the solid line indicates a willingness to pay of £20,000 per QALY; simulations below these lines are considered to be cost effective at the respective threshold level.
The cost-effectiveness acceptability curve (Fig. 7) shows that the probability of tiotropium add-on therapy to usual care being a cost-effective strategy versus usual care alone is 66 % at a willingness to pay of £30,000 per QALY gained and 45 % for a willingness to pay of £20,000.
Scenario Analyses
Including a risk for mortality following a severe exacerbation with hospitalisation reduced the ICER by around £2,000 per QALY gained (from £21,906 to £19,764).
Results of the scenario analyses on the model time horizon showed that the ICER was moderately sensitive to variations in the time horizon, with ICERs of £31,726, £24,538 and £23,301 per QALY gained for time horizons of 48 weeks, 3 years and 5 years, respectively. 
Discussion
This cost-effectiveness analysis investigated cost and QALY outcomes over a lifetime horizon for a cohort of patients with uncontrolled asthma who had tiotropium Respimat Ò added to their usual controller therapy. The time horizon is consistent with previous studies [20] and with NICE guidelines for the health technology assessment of a chronic condition [21] .
To our knowledge, this is the first published economic evaluation of tiotropium in asthma. The well-characterised, prospective PrimoTinA-asthma Ò clinical trials measured ACQ outcomes and thus control could be quantified directly at the patient level rather than needing to be imputed (e.g. from diaries or other sources) as has been the case for other economic models in asthma. Therefore, it is likely that the Markov model created for this study was able to approximate the clinical pathway of asthma control with greater accuracy than previous models that have used similar health states such as 'successful control'/'suboptimal control' [22] , 'chronic'/'acute' asthma [23, 24] or 'day-to-day symptoms' [20] .
A further advantage of the PrimoTinA-asthma Ò trials is that tiotropium was added on to a stable background of high-dose ICS/LABA and other asthma medication; this is a realistic approximation of the treatment of patients with severe asthma and, therefore, the results are generalisable for this population. Additionally, the GINA-recommended level of ICS approximates well to the high-dose ICS levels recommended by the BTS/SIGN guidelines (more than 800 lg of budesonide and 400 lg of fluticasone); therefore, the results are particularly relevant for the UK setting [1, 2] .
A possible limitation of the study is the assumption that the stable treatment effect observed throughout weeks 9-48 of the clinical trial would be maintained over the lifetime horizon. The impact of this assumption was tested by varying the time horizon of the analysis down to the clinical trial period (48 weeks); this analysis demonstrated that cost effectiveness of tiotropium add-on therapy compared with usual care would remain below or close to £30,000 per QALY gained. A further potential limitation of the study is the assumption that all patients persisted with treatment throughout the lifetime horizon at the adherence rates observed in the PrimoTinA-asthma Ò clinical trials. The impact of treatment discontinuation and treatment switching was not investigated in the model in order to ensure the model remained clear and able to replicate the PrimoTinA- Ò trial results. These limitations indicate a need for further research to confirm the long-term treatment effects of tiotropium and adherence rates in this severe asthma patient population.
The EQ-5D was used to measure health-related quality of life (HR-QOL) in the PrimoTinA-asthma Ò clinical trials as it is the most accepted health-related utility measure and the required outcomes measure for health technology assessment in the UK and many other countries [21, 25] . However, findings in the literature suggest that use of a respiratory disease specific measure of HR-QOL within the analysis might have produced results that are more responsive to health state changes at the individual patient level [26, 27] .
Patients who remain uncontrolled and symptomatic despite receiving at least a moderate-to high-dose ICS in combination with a LABA generate a substantial economic burden to healthcare systems [1, 2] . Asthma-related costs can account for up to 2 % of healthcare expenditure [28] and exacerbations are key drivers of this economic burden [29] . This analysis demonstrates that although tiotropium as add-on therapy to usual care increased medication costs for patients, this increase was partially offset by cost savings due to fewer exacerbations. Therefore, tiotropium add- QALYs quality-adjusted life-years Fig. 5 Incremental cost-effectiveness ratios of tiotropium add-on therapy to usual care vs. usual care alone following variation of key model inputs (one-way sensitivity analysis). ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year Fig. 6 Cost-effectiveness scatter plot for tiotropium add-on therapy to usual care vs. usual care alone. QALY quality-adjusted life-year on therapy is effective in reducing the economic burden associated with exacerbations. There are limited treatment options for patients who experience persistent uncontrolled asthma and frequent exacerbations despite GINA step 4 treatment [1] ; oral glucocorticosteroid use is inexpensive but is associated with severe side effects, omalizumab is costly but is only indicated in patients with elevated serum levels of IgE, and evidence for the added benefit of theophylline and leukotriene receptor antagonists is poor [1] . In contrast, the PrimoTinA-asthma Ò clinical trials demonstrate that tiotropium significantly improves the change from baseline in both peak and trough FEV 1 , significantly reduces severe asthma exacerbations and increases time to first severe exacerbation whilst displaying a similar safety profile to placebo [7] . The analysis conducted in this study further indicates that the addition of tiotropium generates 0.24 additional QALYs over a lifetime horizon for this patient group. The PSA demonstrated that there is only a very small degree of uncertainty around this utility gain; an average utility gain of 0.239 and credible interval of 0.237-0.241 was observed in the PSA.
The base-case ICER determined by this analysis was within the commonly accepted £20,000-£30,000 per QALY gained willingness-to-pay threshold used in the UK. Sensitivity analyses assessing the impact of key model inputs showed that the model was most sensitive to changes in the costs of the uncontrolled and partly controlled asthma control health states; none of these variations resulted in an ICER above £30,000. Furthermore, the PSA demonstrated a 66 % likelihood of the base-case ICER being below £30,000 per QALY gained.
Conclusion
A Markov model was developed to analyse the cost effectiveness of tiotropium as add-on to usual care over a lifetime horizon. Adult patients with asthma uncontrolled despite treatment with high-dose ICS/LABA were considered in the analysis. The model predicted that tiotropium add-on therapy to usual care reduced exacerbations and improved asthma control with an ICER of £21,906 per QALY gained and a 66 % likelihood of cost effectiveness at a willingness to pay of £30,000 per QALY gained, when compared to with usual care treatment (high-dose ICS/ LABA) with or without additional controllers. Future research should investigate the long-term treatment effectiveness of tiotropium and should include comparison of the cost effectiveness of tiotropium with alternative treatment options for patients who remain uncontrolled despite treatment at GINA step 4. Fig. 7 Cost-effectiveness acceptability curve for tiotropium add-on therapy to usual care vs. usual care alone. QALY quality-adjusted life-year
